Last edition
News about "Dr. Ditte Primdahl"
Hemispherian Secures FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1
Hemispherian AS has received FDA clearance for its IND application to begin a Phase 1 trial of GLIX1, a first-in-class small molecule targeting DNA repair vulnerabilities in glioblastoma and other solid tumours.
Dr. Ditte Primdahl | 05/08/2025 | By Mrinmoy Dey | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members